Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity (2016 - 2026)

Corvus Pharmaceuticals' Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $253.2 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 325.98% to $253.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $494.2 million through Mar 2026, up 96.35% year-over-year, with the annual reading at $71.1 million for FY2025, 3.21% up from the prior year.
  • Liabilities and Shareholders Equity came in at $253.2 million for Q1 2026, up from $71.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $253.2 million in Q1 2026 to a low of $40.1 million in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $68.2 million (2022), against an average of $79.0 million.
  • Year-over-year, Liabilities and Shareholders Equity crashed 42.54% in 2023 and then soared 325.98% in 2026.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity stood at $68.2 million in 2022, then plummeted by 33.25% to $45.6 million in 2023, then skyrocketed by 51.27% to $68.9 million in 2024, then rose by 3.21% to $71.1 million in 2025, then soared by 256.02% to $253.2 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Liabilities and Shareholders Equity are $253.2 million (Q1 2026), $71.1 million (Q4 2025), and $80.5 million (Q3 2025).